• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by LENZ Therapeutics Inc.

    4/28/26 4:42:46 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email
    DEFA14A 1 a2026defa14a.htm DEFA14A 2026 DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Filed by the Registrant ☒
    Filed by a party other than the Registrant ☐
    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☒
    Definitive Additional Materials
    ☐
    Soliciting Material under §240.14a-12
    LENZ THERAPEUTICS, INC.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    ☒
    No fee required
    ☐
    Fee paid previously with preliminary materials
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


     
    Your control number Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 12, 2026 For Stockholders of record as of April 14, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/LENZ Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved LENZ Therapeutics, Inc. Annual Meeting of Stockholders Friday, June 12, 2026 10:00 AM, Pacific Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/LENZ to register to attend the Annual Meeting You must register to attend the meeting online and/or participate at www.proxydocs.com/LENZ For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/LENZ To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 2, 2026. styleINA P.O. BOX 8016, CARY, NC 27512-9903 SEE REVERSE FOR FULL AGENDA


     
    PROPOSAL 1. To elect three Class II directors to hold office until our 2029 annual meeting of stockholders, each until their respective successors are elected and qualified. 1.01 Evert Schimmelpennink 1.02 Jeff George 1.03 Shelley Thunen 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR EACH OF THE NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSAL 2 LENZ Therapeutics, Inc. Annual Meeting of Stockholders


     
     
    Get the next $LENZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    5/12/2026$12.00Overweight → Neutral
    Piper Sandler
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    More analyst ratings

    $LENZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccollum James W bought $239,278 worth of shares (10,500 units at $22.79) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    11/10/25 4:13:53 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Chevallard Daniel R. bought $50,017 worth of shares (2,198 units at $22.76), increasing direct ownership by 69% to 5,386 units (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    11/7/25 7:42:43 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chevallard Daniel R. bought $49,988 worth of shares (3,188 units at $15.68) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    5/15/24 4:13:06 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENZ Therapeutics to Participate in Upcoming Investor Conferences

    SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: William Blair 46th Annual Growth Stock Conference Date: June 2, 2026Location: Chicago, ILFormat: 1x1 investor meetings 2026 Jefferies Global Healthcare ConferenceDate: June 3, 2026Location: New York, NYFormat: 1x1 investor meetings Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Jun

    5/26/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presby

    5/11/26 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

    SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.

    5/4/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    SEC Filings

    View All

    SEC Form 10-Q filed by LENZ Therapeutics Inc.

    10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/11/26 4:10:32 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/11/26 4:07:49 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by LENZ Therapeutics Inc.

    DEFA14A - LENZ Therapeutics, Inc. (0001815776) (Filer)

    4/28/26 4:42:46 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by George Jeffrey P.

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/30/26 8:47:03 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Schimmelpennink Evert B.

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/30/26 8:46:58 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chevallard Daniel R.

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/30/26 8:46:52 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LENZ Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded LENZ Therapeutics from Overweight to Neutral and set a new price target of $12.00

    5/12/26 8:21:06 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

    Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

    4/14/25 8:17:08 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on LENZ Therapeutics with a new price target

    TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

    3/18/25 7:53:26 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lucy Therapeutics Appoints Kim Drapkin as Board Chair

    Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

    10/15/24 8:00:00 AM ET
    $ABOS
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

    Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv

    6/10/24 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Financials

    Live finance-specific insights

    View All

    LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presby

    5/11/26 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

    SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.

    5/4/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

    Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ)

    3/24/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

    SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/14/24 4:00:05 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by LENZ Therapeutics Inc.

    SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/8/24 5:08:56 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by LENZ Therapeutics Inc.

    SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

    7/29/24 4:12:50 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care